Lanreotide
- Generic Name
- Lanreotide
- Brand Names
- Somatuline
- Drug Type
- Small Molecule
- Chemical Formula
- C54H69N11O10S2
- CAS Number
- 108736-35-2
- Unique Ingredient Identifier
- 0G3DE8943Y
- Background
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen Pharmaceuticals as...
- Indication
Lanreotide is indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy. It is also indicated in the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumo...
- Associated Conditions
- Acromegaly, Carcinoid Syndrome, Unresectable, locally advanced enteropancreatic neuroendocrine tumors, Unresectable, locally advanced well- or moderately-differentiated Gastroenteropancreatic Neuroendocrine Tumors, Unresectable, metastatic enteropancreatic neuroendocrine tumors, Unresectable, metastatic well- or moderately-differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Associated Therapies
- -
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT05477576
- Locations
- 🇪🇸
Research Facility, Zaragoza, Spain
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 49
- Registration Number
- NCT05048901
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳National Cheng Kung University Hospita, Tainan, Taiwan
🇨🇳Changhua Christian Hospital, Changhua, Taiwan
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-09-05
- Target Recruit Count
- 69
- Registration Number
- NCT04427787
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
- Conditions
- Interventions
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Antonio Fojo
- Target Recruit Count
- 40
- Registration Number
- NCT03946527
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT03083210
- Locations
- 🇰🇷
Youngsuk Park, Seoul, Korea, Republic of
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Duke University
- Target Recruit Count
- 22
- Registration Number
- NCT03043664
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Lexington Medical Center, Columbia, South Carolina, United States
Lanreotide in the Treatment of Small Bowel Motility Disorders
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 12
- Registration Number
- NCT03012594
- Locations
- 🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇺🇸Lenox Hill Hospital, New York, New York, United States
Circulating Tumor Cells and Tumor DNA in HCC and NET
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 167
- Registration Number
- NCT02973204
- Locations
- 🇩🇰
Department of Hepatology and Gastroenterology, Aarhus, Aarhus C, Denmark
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
- Conditions
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT02859064
- Locations
- 🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Research Medical Center/HCA Midwest, Kansas City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.